Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma.

ABSTRACT:

Purpose

There are limited and no standard therapies for recurrent glioblastoma. We herein report the antitumour activity and safety of sintilimab, bevacizumab and temozolomide (TMZ) in recurrent glioblastoma.

Methods

We retrospectively analysed eight patients with recurrent glioblastoma treated with sintilimab (200 mg) every three weeks + bevacizumab (10 mg/kg) every three weeks + TMZ (200 mg/m²orally) (5 days orally every 28 days for a total of four weeks). The primary objective was investigator-assessed median progression-free survival(mPFS). Secondary objectives were to assess the 6-month PFS, objective response rate (ORR) and duration of response (DOR) accroding to RANO criteria.

Results

The mPFS time for 8 patients was 3.340 months (95% CI: 2.217-4.463), The long

SUBMITTER: Lu Y 

PROVIDER: S-EPMC10811825 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature